Eterna Therapeutics secures up to $10M equity line from Lincoln Park Capital

Ernexa Therapeutics Inc.

Lincoln Park committed to buy up to $10M of common stock over 24 months at Company's discretion.
Company issued 73,659 shares as commitment fee; purchases subject to volume and price limits.
No upper limit on purchase price per share; Lincoln Park cannot short or hedge during term.
Sales limited to 19.99% of outstanding shares unless stock price exceeds $3.6094 or shareholder approval obtained.
Company may terminate agreement with one business day notice; no penalties or liquidated damages.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ernexa Therapeutics Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2023-04-05).

Action: entry
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Value: up to $10.0 million
Effective: 2023-04-05

Exact text from the filing

On April 5, 2023, Eterna Therapeutics Inc., a Delaware corporation (the " Company "), entered into a purchase agreement (the " Purchase Agreement ") and a registration rights agreement (the " Registration Rights Agreement ") with Lincoln Park Capital Fund, LLC (" Lincoln Park "), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock

View on SEC.gov

Browse all material agreements →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-017671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.